Since the median age at cancer diagnosis in SMARCA4 mutation carriers is lower as compared to BRCA1/BRCA2 mutation carriers, the prophylactic surgery should be offered at least earlier, preferably below the age of 22. The gene discussed is SMARCA4; the disease is cancer.